Back
32
Also listed as
DSNKY
OTC
Day Range
$19.30
$20.10
52-Week Range
$16.81
$29.15
Volume
379
50D / 200D Avg
$19.37
/
$22.56
Prev Close
$18.92
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 0.1 | 0.4 |
| P/B | — | 2.9 |
| ROE % | — | 3.8 |
| Net Margin % | 15.7 | 3.9 |
| Rev Growth 5Y % | 18.3 | 10.0 |
| D/E | — | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$341.34
$320.76 – $390.50
|
3400 B | 3 |
| FY2029 |
$276.96
$260.26 – $316.85
|
3000 B | 3 |
| FY2028 |
$228.10
$214.35 – $260.95
|
2600 B | 4 |
Key Takeaways
Revenue grew 18.32% annually over 5 years — strong growth
Earnings grew 47.34% over the past year
Net margin of 15.68% shows strong profitability
Negative free cash flow of -134.03B
P/E of 0.12 — trading at a low valuation
PEG of 0.43 suggests growth is underpriced
Growth
Revenue Growth (5Y)
18.32%
Revenue (1Y)17.77%
Earnings (1Y)47.34%
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net Margin15.68%
Op. Margin17.60%
Safety
Debt / Equity
N/A
Current RatioN/A
Interest Coverage28.00
Valuation
P/E Ratio
0.12
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 17.77% | Revenue Growth (3Y) | 21.47% |
| Earnings Growth (1Y) | 47.34% | Earnings Growth (3Y) | 64.58% |
| Revenue Growth (5Y) | 18.32% | Earnings Growth (5Y) | 40.47% |
| Profitability | |||
| Revenue (TTM) | 1.89T | Net Income (TTM) | 295.76B |
| ROE | N/A | ROA | N/A |
| Gross Margin | 77.96% | Operating Margin | 17.60% |
| Net Margin | 15.68% | Free Cash Flow (TTM) | -134.03B |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | 28.00 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 0.12 | P/B Ratio | N/A |
| P/S Ratio | 0.02 | PEG Ratio | 0.43 |
| EV/EBITDA | N/A | Dividend Yield | 0.02% |
| Market Cap | 36.84B | Enterprise Value | N/A |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.89T | 1.60T | 1.28T | 1.04T | 962.52B |
| Net Income | 295.76B | 200.73B | 109.19B | 66.97B | 75.96B |
| EPS (Diluted) | 155.87 | 104.62 | 56.91 | 34.91 | 39.11 |
| Gross Profit | 1.47T | 1.19T | 914.95B | 682.09B | 624.23B |
| Operating Income | 331.93B | 211.59B | 120.58B | 73.03B | 63.80B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#342 of 616
Recent Activity
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026